<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1688-0390</journal-id>
<journal-title><![CDATA[Revista Médica del Uruguay]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Méd. Urug.]]></abbrev-journal-title>
<issn>1688-0390</issn>
<publisher>
<publisher-name><![CDATA[Sindicato Médico del Uruguay]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1688-03902021000301701</article-id>
<article-id pub-id-type="doi">10.29193/rmu.37.3.11</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Trombocitopenia trombótica inducida por vacuna. Primer reporte nacional]]></article-title>
<article-title xml:lang="en"><![CDATA[Vaccine-associated immune thrombosis and thrombocytopenia. First national report]]></article-title>
<article-title xml:lang="pt"><![CDATA[Trombocitopenia trombótica induzida por vacina (VITT). Primeiro relatório nacional]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Roca]]></surname>
<given-names><![CDATA[Federico]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Danza]]></surname>
<given-names><![CDATA[Álvaro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pippo]]></surname>
<given-names><![CDATA[Antonella]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Borgia]]></surname>
<given-names><![CDATA[Ignacio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de la República Facultad de Medicina ]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de la República Facultad de Medicina ]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Asociación Española Primera de Socorros Mutuos  ]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Asociación Española Primera de Socorros Mutuos  ]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2021</year>
</pub-date>
<volume>37</volume>
<numero>3</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S1688-03902021000301701&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S1688-03902021000301701&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S1688-03902021000301701&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  la vacunación contra SARS-CoV-2 es una herramienta imprescindible en el combate contra la pandemia de COVID-19. La vacuna desarrollada en colaboración entre la Universidad de Oxford y el laboratorio de productos farmacéuticos AstraZeneca (AZN) ha demostrado buena eficacia, pero ha habido reporte de trombosis venosas.  Caso clínico:  se presenta el caso de un paciente de 70 años, de sexo masculino, que 7 días después de la administración de la primera dosis de la vacuna AZN desarrolla trombosis venosa profunda de ambos miembros inferiores y tromboembolismo pulmonar. Coincide con trombocitopenia de 15.000/mm3, descenso del fibrinógeno y elevación de los D-dímeros. La situación clínica evoca el planteo de trombocitopenia trombótica inducida por vacuna (VITT). Se realizó tratamiento con inmunoglobulinas intravenosas, metilprednisolona y crioprecipitados. Requirió colocación de un filtro de la vena cava inferior. Una vez mejorado el recuento plaquetario se instaló tratamiento anticoagulante con apixaban. Evolucionó favorablemente.  Discusión:  se trata del primer reporte nacional de VITT. Las trombosis subsiguientes a la vacuna de AZN pueden verse con las vacunas que comparten la misma plataforma vacunal (adenovirus inactivado). Se han reportado casos fundamentalmente en menores de 60 años y en topografías inhabituales. Este caso tiene la particularidad de que se trata de un paciente mayor de 60 años, que ya había tenido COVID-19 cinco meses antes y que se presenta con una trombosis en sitios habituales. El manejo terapéutico se adecuó a las pautas internacionales. El caso deja un aprendizaje relevante tanto en lo que refiere al diagnóstico precoz como al manejo terapéutico.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction:  vaccines against SARS-CoV-2 are an essential tool against the COVID-19 pandemic. The vaccine developed in collaboration with the University of Oxford and the AstraZeneca (AZN) laboratory has proved to be effective, although venous thrombosis have been reported.  Clinical case:  the study presents the case of a 70 year old male patient who, 7 days after receiving the first dose of the AZN vaccination develops deep vein thrombosis (DVT) in the lower extremities and pulmonary embolism. Simultaneously, thrombocytopenia is 15.000/mm3, fibrinogen levels drop D-dimer levels are elevated. The clinical situation leads to the suspicion of vaccine-associated immune thrombosis and thrombocytopenia (VITT). The patient was treated with intravenous immune globulin, methylprednisolone and cryoprecipitates, requiring a filter to be placed in the inferior vena cava. Once platelets count improved, anti-coagulation therapy including apixaban was commenced, evolution being good.  Discussion:  this is the first national report on VITT. Thrombosis after the AZN vaccination may be seen in other vaccines that use the same vaccine platform (inactive adenovirus). Cases have been reported mainly in patients younger than 60 years old and in unusual topographies. In particular, this case presents a male patient that is older than 60 years old, who had already been infected with COVID-19 five months before and who currently consults with thrombosis in regular sites. Therapeutic handling observed international guidelines. The case contributes relevant data both in terms of early diagnosis and therapeutic handling.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo:  Introdução: a vacinação contra a SARS-CoV-2 é uma ferramenta essencial na luta contra a pandemia de COVID-19. A vacina desenvolvida pela colaboração entre a Universidade de Oxford e o laboratório farmacêutico AstraZeneca (AZN) tem demonstrado boa eficácia, mas foram relatados casos de trombose venosa.  Caso clínico:  apresenta-se o caso de um paciente do sexo masculino, 70 anos, que 7 dias após a administração da primeira dose da vacina AZN desenvolveu trombose venosa profunda de ambos os membros inferiores e tromboembolismo pulmonar. Coincide com trombocitopenia de 15.000 / mm3, diminuição do fibrinogênio e aumento dos D-dímeros. A situação clínica lembra a trombocitopenia trombótica induzida por vacina (VITT). O tratamento foi realizado com imunoglobulinas intravenosas, metilprednisolona e crioprecipitados. Foi necessário colocar um filtro de veia cava inferior. Uma vez que a contagem de plaquetas melhorou, o tratamento anticoagulante com apixaban foi instalado. O paciente favoravelmente.  Discussão: este é o primeiro relatório nacional de VITT. As tromboses subseqüentes à vacina AZN podem ser vistas com vacinas que compartilham a mesma plataforma (adenovírus inativado). Os casos foram relatados principalmente em pessoas com menos de 60 anos de idade e em topografias incomuns. Este caso tem a particularidade de se tratar de um paciente com mais de 60 anos, já com COVID-19 há cinco meses e que apresenta trombose em sítios comuns. O manejo terapêutico foi adaptado às diretrizes internacionais. O caso deixa um aprendizado relevante tanto no que diz respeito ao diagnóstico precoce quanto ao manejo terapêutico.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Trombocitopenia]]></kwd>
<kwd lng="es"><![CDATA[Trombosis]]></kwd>
<kwd lng="es"><![CDATA[Vacuna COVID-19 AstraZeneca]]></kwd>
<kwd lng="en"><![CDATA[Thrombocytopenia]]></kwd>
<kwd lng="en"><![CDATA[Thrombosis]]></kwd>
<kwd lng="en"><![CDATA[COVID-19 Vaccine AstraZeneca]]></kwd>
<kwd lng="pt"><![CDATA[Trombocitopenia]]></kwd>
<kwd lng="pt"><![CDATA[Trombose]]></kwd>
<kwd lng="pt"><![CDATA[Vacina COVID-19 AstraZeneca]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<collab>World Health Organization</collab>
<source><![CDATA[Draft landscape of COVID-19 candidate vaccines]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Voysey]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Clemens]]></surname>
<given-names><![CDATA[SAC]]></given-names>
</name>
<name>
<surname><![CDATA[Madhi]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Weckx]]></surname>
<given-names><![CDATA[LY]]></given-names>
</name>
<name>
<surname><![CDATA[Folegatti]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Aley]]></surname>
<given-names><![CDATA[PK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2 an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2021</year>
<volume>397</volume>
<numero>10269</numero>
<issue>10269</issue>
<page-range>9-111</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<collab>European Medicines Agency</collab>
<source><![CDATA[COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets]]></source>
<year>2021</year>
<publisher-loc><![CDATA[Amsterdam ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Franchini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Liumbruno]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Pezzo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[COVID-19 Vaccine-associated Immune thrombosis and thrombocytopenia (VITT) diagnostic and therapeutic recommendations for a new syndrome]]></article-title>
<source><![CDATA[Eur J Haematol]]></source>
<year>2021</year>
<volume>107</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>173-80</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Danza]]></surname>
<given-names><![CDATA[Á]]></given-names>
</name>
<name>
<surname><![CDATA[Frantchez]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sobre la vacuna desarrollada en Reino Unido (Universidad de Oxford-AstraZeneca)]]></article-title>
<source><![CDATA[Rev Méd Urug]]></source>
<year>2021</year>
<volume>37</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Levi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Toh]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Thachil]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Watson]]></surname>
<given-names><![CDATA[HG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guidelines for the diagnosis and management of disseminated intravascular coagulation British Committee for Standards in Haematology]]></article-title>
<source><![CDATA[Br J Haematol]]></source>
<year>2009</year>
<volume>145</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>24-33</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Greinacher]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Thiele]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Warkentin]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
<name>
<surname><![CDATA[Weisser]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kyrle]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Eichinger]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A prothrombotic thrombocytopenic disorder resembling heparin-induced thrombocytopenia following coronavirus-19 vaccination]]></article-title>
<source><![CDATA[Research Square Preprint]]></source>
<year>2021</year>
<page-range>1-10</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pavord]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lester]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Makris]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Scully]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hunt]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[Guidance from the Expert Haematology Panel (EHP) on Covid-19 Vaccine-induced Immune Thrombocytopenia and Thrombosis (VITT)]]></source>
<year>2021</year>
<publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[British Society for Haematology]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramasamy]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Minassian]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Ewer]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Flaxman]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Folegatti]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Owens]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002) a single-blind, randomised, controlled, phase 2/3 trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2021</year>
<volume>396</volume>
<numero>10267</numero>
<issue>10267</issue>
<page-range>1979-93</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<collab>Centers for Diseases and Prevention</collab>
<source><![CDATA[Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States]]></source>
<year>2021</year>
<publisher-name><![CDATA[CDC]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
